Role of the BCA2 ubiquitin E3 ligase in hormone responsive breast cancer

Open Cancer Journal

Volumn 3, Issue SPEC. ISSUE 1, 2010, Pages 116-123

  Burger, Angelika M ^a   Kona, Fathima ^a   Amemiya, Yutaka ^b   Gao, Yuguang ^b   Bacopulos, Stephanie ^b   Seth, Arun K ^b,c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Sunnybrook Health Sciences Centre   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

BCA2; Breast cancer; Hormone responsive; SUMO; Transcription

Indexed keywords

BREAST CANCER ASSOCIATED PROTEIN 2; ESTROGEN; ESTROGEN RECEPTOR; MESSENGER RNA; PROGESTERONE RECEPTOR; PROTEIN BCA2; PROTEIN UBC9; RING FINGER PROTEIN; SUMO PROTEIN; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BINDING SITE; BREAST CANCER; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; ENZYME ACTIVITY; HOMEOSTASIS; HUMAN; INTRADUCTAL CARCINOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; SIGNAL TRANSDUCTION; SUMOYLATION; TRANSCRIPTION REGULATION;

EID: 78249246032     PISSN: None     EISSN: 18740790     Source Type: Journal    
DOI: 10.2174/1874079001003010116     Document Type: Article

References (44)

1. Desterro JMP, Rodriguez MS, Hay RT. Regulation of transcription factors by protein degradation. Cell Mol Life Sci 2007; 57: 1207-19.
2. Zhang Z, Liao B, Xu M, Jin Y. Post-translational modification of POU domain transcription factor Oct-4 by SUMO-1. FASEB J 2007; 21: 3042-51.
3. Verger A, Perdomo J, Crossley M. Modification with SUMO. A role in transcriptional regulation. EMBO Rep 2003; 4: 137-42.
4. Nishida T, Terashima M, Fukami K, Yamada Y. PIASy controls ubiquitination-dependent proteasomal degradation of Ets-1. Biochem J 2007; 405: 481-8.
5. Chen C, Seth, AK, Aplin AE. Genetic and expression aberrations of E3 ubiquitin ligases in human breast cancer. Mol Cancer Res 2006; 4: 695-707.
6. von Mikecz A. The nuclear ubiquitin-proteasome system. J Cell Sci 2006; 119: 1977-84.
7. Huang J, Li X, Maguire CA, Hilf R, Bambara RA, Muyan M. Binding of estrogen receptor beta to estrogen response element in situ is independent of estradiol and impaired by its amino terminus. Mol Endocrinol 2005; 19: 2696-712.
8. Feng Y, Manka D, Wagner KU, Khan SA. Estrogen receptor-alpha expression in the mammary epithelium is required for ductal and alveolar morphogenesis in mice. Proc Natl Acad Sci USA 2007; 104: 14718-23.
9. Eakin CM, Maccoss MJ, Finney GL, Klevit RE. Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase. Proc Natl Acad Sci USA 2007; 104: 5794-9.
10. Sentis S, Le Romancer M, Bianchin C, Rostan MC, Corbo L. Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Mol Endocrinol 2005; 19: 2671-84.
11. Burger A, Li H, Zhang XK, et al. Breast cancer genome anatomy: correlation of morphological changes in breast carcinomas with expression of the novel gene product Di12. Oncogene 1998; 16: 327-33.
12. Burger AM, Gao Y, Amemiya Y, et al. A novel RING-type ubiquitin ligase breast cancer-associated gene 2 correlates with outcome in invasive breast cancer. Cancer Res 2005; 65: 10401-12.
13. Burger A, Amemiya Y, Kitching R, Seth AK. Novel RING E3 ubiquitin ligases in breast cancer. Neoplasia 2006; 8: 689-95.
14. Reid G, Hubner MR, Metivier R, et al. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell 2003; 11: 695-707.
15. Lonard DM, Nawaz Z, Smith CL, O'Malley BW. The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. Mol Cell 2000; 5: 939-48.
16. Wijayaratne AL, McDonnell DP. The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem 2001; 276: 35684-92.
17. Fan S, Wang J, Yuan R, et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 1999; 284: 1354-6.
18. Saji S, Okumura N, Eguchi H, et al. MDM2 enhances the function of estrogen receptor alpha in human breast cancer cells. Biochem Biophys Res Commun 2001; 281: 259-65.
19. Nawaz Z, Lonard DM, Smith CL, et al. The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily. Mol Cell Biol 1999; 19: 1182-9.
20. Nilsson S, Gustafsson J. Estrogen receptor transcription and transactivation: Basic aspects of estrogen action. Breast Cancer Res 2000; 2: 360-6.
21. Klinge CM. Estrogen receptor interaction with co-activators and co-repressors. Steroids 2000; 65: 227-51.
22. Chu I, Arnaout A, Loiseau S, et al. Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer. J Clin Invest 2007; 117: 2205-15.
23. Reddel RR, Murphy LC, Sutherland RL. Factors affecting the sensitivity of T-47D human breast cancer cells to tamoxifen. Cancer Res 1984; 44: 2398-405.
24. Feng D, Kan YW. The binding of the ubiquitous transcription factor Sp1 at the locus control region represses the expression of beta-like globin genes. Proc Natl Acad Sci USA 2005; 102: 9896-900.
25. Karin M, Liu Z, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 1997; 9: 240-6.
26. Bing D, Feng-Qi Z. Involvement of the ubiquitous Oct-1 transcription factor in hormonal induction of ß-casein gene expression. Biochem J 2007; 401: 57-64.
27. Gordon S, Akopyan G, Garban H, Bonavida B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene 2006; 25: 1125-42.
28. Helmer EB, Raaka BM, Samuels HH. Hormone-dependent and -independent transcriptional activation by thyroid hormone receptors are mediated by different mechanisms. Endocrinology 1996; 137: 390-9.
29. Xu J, Thompson KL, Shephard LB, Hudson LG, Gill GN. T3 receptor suppression of Sp1-dependent transcription from the epidermal growth factor receptor promoter via overlapping DNA-binding sites. J Biol Chem 1993; 268: 16065-73.
30. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge, GW Jr. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997; 17: 3629-39.
31. Garcia-Dominguez M, Reyes JC. SUMO association with repressor complexes, emerging routes for transcriptional control. Biochim Biophys Acta 2009; 1789: 451-9.
32. Mo YY, Yu Y, Theodosiou E, Ee PL, Beck WT. A role for Ubc9 in tumorigenesis. Oncogene 2005; 24: 2677-83.
33. Knipscheer P, Flotho A, Klug H, et al. Ubc9 sumoylation regulates SUMO target discrimination. Mol Cell 2008; 31: 371-82.
34. Kaikkonen S, Jaaskelainen T, Karvonen U, et al. SUMO-specific protease 1 (SENP1) reverses the hormone-augmented SUMOyla-tion of androgen receptor and modulates gene responses in prostate cancer cells. Mol Endocrinol 2009; 23(3): 292-307.
35. Deng Z, Wan M, Sui G. PIASy-mediated sumoylation of Yin Yang 1 depends on their interaction but not the RING finger. Mol Cell Biol 2007; 27: 3780-92.
36. Spengler ML, Brattain MG. Sumoylation inhibits cleavage of Sp1 N-terminal negative regulatory domain and inhibits Sp1-dependent transcription. J Biol Chem 2006; 281: 5567-74.
37. Xu J, Watkins T, Reddy A, Reddy ES, Rao VN. A novel mechanism whereby BRCA1/1a/1b fine tunes the dynamic complex interplay between SUMO-dependent/independent activities of Ubc9 on E2-induced ERalpha activation/repression and degradation in breast cancer cells. Int J Oncol 2009; 34: 939-49.
38. Burger AM, Seth AK. The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur J Cancer 2004; 40: 2217-29.
39. Amemiya Y, Azmi P, Seth A. Autoubiquitination of BCA2 RING E3 ligase regulates its own stability and affects cell migration. Mol Cancer Res 2008; 6: 1385-96.
40. Connor MK, Azmi PB, Subramaniam V, Li H, Seth A. Molecular characterization of ring finger protein 11. Mol Cancer Res 2005; 3: 453-61.
41. Hoeller D, Hecker CM, Dikic I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer 2006; 6: 776-88.
42. Baek SH. A novel link between SUMO modification and cancer metastasis. Cell Cycle 2006; 5: 1492-5.
43. Qi X, Borowicz S, Pramanik R, Schultz RM, Han J, Chen G. Estrogen receptor inhibits c-Jun-dependent stress-induced cell death by binding and modifying c-Jun activity in human breast cancer cells. J Biol Chem 2004; 279: 6769-77.
44. Burger AM, Dai F, Schultes CM, et al. The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function. Cancer Res 2005; 65: 1489-96.